相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells
Chun-shuang Ma et al.
ACTA PHARMACOLOGICA SINICA (2021)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Upfront osimertinib - winner takes it all?
Jordi Remon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Metabolic reprogramming and cancer progression
Brandon Faubert et al.
SCIENCE (2020)
Development and validation of a rapid, robust and sensitive UPLC-QQQ-MS/MS method for simultaneous quantification of GSH metabolism in lung cancer cells
Yu-Fei Zhang et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
Monique B. Nilsson et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Hideaki Ogiwara et al.
CANCER CELL (2019)
UPLC-MS-based metabolomics reveals metabolic dysregulation in ALDH1A1-overexpressed lung adenocarcinoma cells
Yang Wang et al.
METABOLOMICS (2019)
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation
Antoinette van Weverwijk et al.
NATURE COMMUNICATIONS (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
A view on drug resistance in cancer
Neil Vasan et al.
NATURE (2019)
A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer
Ke Huang et al.
CELL METABOLISM (2019)
Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas
Hui-Min Lei et al.
THERANOSTICS (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells
Annemarie Schwab et al.
CANCER RESEARCH (2018)
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Liqin Wang et al.
CELL (2018)
Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
Sanjay Popat
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer
Hong Zhu et al.
THERANOSTICS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Translational and HIF-1 alpha-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides
Laura Hulea et al.
CELL METABOLISM (2018)
Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies
Maria Apicella et al.
CELL METABOLISM (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth
Shiro L. Cramer et al.
NATURE MEDICINE (2017)
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Matthew J. Hangauer et al.
NATURE (2017)
Multifaceted Roles of Glutathione and Glutathione-Based Systems in Carcinogenesis and Anticancer Drug Resistance
Elie Hatem et al.
ANTIOXIDANTS & REDOX SIGNALING (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
David Planchard et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors
Sheri L. Moores et al.
CANCER RESEARCH (2016)
The aldo-keto reductases (AKRs): Overview
Trevor M. Penning
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma
Erin L. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL
Benshang Li et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
GdX/UBL4A Specifically Stabilizes the TC45/STAT3 Association and Promotes Dephosphorylation of STAT3 to Repress Tumorigenesis
Yangmeng Wang et al.
MOLECULAR CELL (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Manuel Hidalgo et al.
CANCER DISCOVERY (2014)
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naive Asian NSCLC patients
Mengmeng Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
分享论文
